Overland Therapeutics Launches with the Mission of Accelerating Global Development of First and Best-in-Class Cell Therapies

South San Francisco, California, May 24, 2024 – Overland Therapeutics (Overland Tx) announced its official launch with a mission to accelerate the global development of first and best-in-class cell therapies.  Seeded by Hillhouse and Allogene Therapeutics (Allogene), Overland Tx combines the cell therapy programs of Overland Pharmaceuticals (Overland Pharma) with the joint venture company previously formed by Overland Pharma and Allogene for the development and commercialization of certain allogeneic cell products licensed from Allogene.

As a result of the strategic restructure, Overland Tx has established fully-integrated, cross-border cell therapy research, development, and GMP manufacturing capabilities in South San Francisco, California and Shanghai, China.  With strong financial backing, Overland Tx is poised to achieve key clinical milestones for its leading programs in 2025.

Overland Tx’s internally developed pipeline includes the near-clinical program, OL-101, a potentially best-in-class GPRC5D / BCMA dual-targeting autologous CAR-T therapy.  Utilizing a tandem design of VHH binders, OL-101 targets two distinct antigens for multiple myeloma to overcome antigen escape and prolong survival in relapsed / refractory multiple myeloma (r/r MM) patients.  The first patient dosing for OL-101 is expected in Q4 2024, and clinical proof-of-concept (PoC) data is anticipated by Q3 2025.  This innovative therapy holds promise to address a major unmet medical need in MM, particularly for patients who are relapsed or refractory to BCMA-directed agents, including CAR-T, ADC, and bispecific therapies, with significant opportunity to move to early line of treatment.

Overland Tx is also developing a proprietary allogeneic gamma delta T cell (γδ T cell) therapy platform to address compelling opportunities in autoimmunity.  As compared to autologous CAR-T therapies, allogeneic cell therapies offer significant advantages, including manufacturing simplicity, reduced cost, and off-the-shelf convenience.  More importantly, it may provide a more favorable safety profile due to its “transient” in-vivo expansion, while still capable of efficiently resetting healthy B-cells in autoimmune diseases.  Overland Tx’s γδ T lead program is on track for clinical trial submission in Q4 2024 and first patient dosing in early 2025.

In addition to its internally developed pipeline, Overland Tx also holds the exclusive license from Allogene to develop, manufacture, and commercialize specific allogeneic cell therapy candidates targeting BCMA, CD70, FLT3, and DLL3 in China, Taiwan, South Korea, and Singapore.

About Overland Therapeutics
Overland Therapeutics is a cross-border biotechnology company with a mission of accelerating the global development of first and best-in-class cell therapies. Headquartered in South San Francisco, Overland Tx has established fully integrated, cross-border cell therapy research, development, and GMP manufacturing capabilities.  Overland Tx is developing both autologous and allogeneic cell therapies to address significant patient unmet needs in hematological malignancies and autoimmune diseases. For more information, please visit www.overlandtx.com.

Media Contact
Sophie Chen
Head of Legal and Compliance and Public Affairs
Overland Therapeutics
schen@overlandpharma.com